alpha-galactosylceramide






595 Article(s)
Download
PMID
Title
Journal
Pub. Date
#Total Relationship(s)
1 9257806 alpha-Galactosylceramide (AGL-517) treatment protects mice from lethal irradiation. Exp Hematol 1997 Aug 2
2 9700507 Antigen-presenting function of mouse CD1: one molecule with two different kinds of antigenic ligands. Immunol Rev 1998 Jun 2
3 9759842 Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes. J Immunol 1998 Oct 1 3
4 9782129 CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998 Oct 19 3
5 9826697 Presentation of peptide antigens by mouse CD1 requires endosomal localization and protein antigen processing. Proc Natl Acad Sci U S A 1998 Nov 24 2
6 9952023 Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CD1d-restricted and Valpha24TCR-mediated manner. Hum Immunol 1999 Jan 4
7 10346936 Syntheses of biotinylated alpha-galactosylceramides and their effects on the immune system and CD1 molecules. J Med Chem 1999 May 20 1
8 10360961 A novel recognition motif of human NKT antigen receptor for a glycolipid ligand. Int Immunol 1999 Jun 2
9 10382765 Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol 1999 Jun 6
10 10384104 A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol 1999 Jul 1 6
11 10450506 Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice. Immunol Rev 1999 Jun 4
12 10452969 Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol 1999 Sep 1 1
13 10452972 Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 1999 Sep 1 4
14 10499917 Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Valpha14 natural killer T cells. J Exp Med 1999 Sep 20 1
15 10523605 Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules. J Exp Med 1999 Oct 18 4
16 10528160 Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999 Nov 1 2
17 10537282 Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res 1999 Oct 15 1
18 10570271 A distinct IL-18-induced pathway to fully activate NK T lymphocytes independently from TCR engagement. J Immunol 1999 Dec 1 2
19 10639149 Involvement of decidual Valpha14 NKT cells in abortion. Proc Natl Acad Sci U S A 2000 Jan 18 4
20 10675273 alpha-galactosylceramide induces early B-cell activation through IL-4 production by NKT cells. Cell Immunol 2000 Jan 10 3
21 10692041 Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology 2000 Feb 2
22 10779745 Analysis of human V alpha 24+ CD4+ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 2000 May 1 3
23 10822576 Synthesis of NBD-alpha-galactosylceramide and its immunologic properties. Org Lett 1999 Aug 12 1
24 10878339 Membrane lymphotoxin is required for the development of different subpopulations of NK T cells. J Immunol 2000 Jul 15 2
25 10882410 The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immunol 2000 Jul 1
26 10884613 CD1-mediated antigen presentation of glycosphingolipids. Microbes Infect 2000 May 2
27 10886786 Differences in the ligand specificity between CD1d-restricted T cells with limited and diverse T-cell receptor repertoire. Scand J Immunol 2000 Jul 3
28 10900007 alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci U S A 2000 Jul 18 2
29 10940881 Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Eur J Immunol 2000 Jul 2
30 11035073 Fas/Fas ligand interactions promote activation-induced cell death of NK T lymphocytes. J Immunol 2000 Oct 15 1
31 11099306 Requirement for IFN-gamma in IL-12 production induced by collaboration between v(alpha)14(+) NKT cells and antigen-presenting cells. Int Immunol 2000 Dec 2
32 11119508 Activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect Immun 2001 Jan 3
33 11123351 Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of V alpha 14 NK T cells. J Immunol 2001 Jan 1 4
34 11145671 IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells. J Immunol 2001 Jan 15 3
35 11145860 Recognition and function of Valpha14 NKT cells. Semin Immunol 2000 Dec 3
36 11145862 Molecular biology of NK T cell specificity and development. Semin Immunol 2000 Dec 1
37 11150537 Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J Immunol Methods 2001 Jan 1 2
38 11164462 Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells. Mech Ageing Dev 2000 Dec 20 3
39 11257133 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001 Mar 19 3
40 11264173 TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 2001 Apr 1 2
41 11304550 The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J Exp Med 2001 Apr 16 4
42 11306921 The role of alpha-galactosylceramide-activated Valpha14 natural killer T cells in the regulation of Th2 cell differentiation. Int Arch Allergy Immunol 2001 Jan-Mar 4
43 11342617 Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol 2001 May 15 3
44 11358978 CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus. J Leukoc Biol 2001 May 2
45 11385616 Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. Eur J Immunol 2001 Jun 3
46 11431415 Crucial amino acid residues of mouse CD1d for glycolipid ligand presentation to V(alpha)14 NKT cells. Int Immunol 2001 Jul 2
47 11466360 Activating immunity in the liver. I. Liver dendritic cells (but not hepatocytes) are potent activators of IFN-gamma release by liver NKT cells. J Immunol 2001 Aug 1 1
48 11489950 CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 2001 Aug 6 1
49 11533710 The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001 Sep 2
50 11564825 Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 2001 Oct 1 1